Inventor · disambiguated record
Martin P. Maguire
Also filed as: MAGUIRE MARTIN · MAGUIRE MARTIN P
34 granted patents·28 pending applications·3,633 citations·filing 1993–2025
98Inventor score
Files withMILESTONE PHARMACEUTICALS INC31AVENTIS PHARMA INC9RHONE POULENC RORER PHARMA9AVENTIS PHARM PROD INC3ORE PHARMACEUTICALS INC2
Top patents by PatentIndex Score
62 records- 0199US6528526B1Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2000·Granted Mar 4, 2003·305 cites·37 claims
- 0299US6524347B1Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2000·Granted Feb 25, 2003·307 cites·11 claims
- 0399US6180632B1Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARM PROD INC·Filed 1998·Granted Jan 30, 2001·395 cites·79 claims
- 0499US6057320ABis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseAVENTIS PHARM PROD INC·Filed 1997·Granted May 2, 2000·148 cites·13 claims
- 0599USRE36256EBis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1997·Granted Jul 20, 1999·183 cites·20 claims
- 0699US5646153ABis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1995·Granted Jul 8, 1997·259 cites·18 claims
- 0799US5480883ABis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1993·Granted Jan 2, 1996·383 cites·20 claims
- 0898US5710158AAryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1994·Granted Jan 20, 1998·339 cites·14 claims
- 0997US6159978AQuinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARM PROD INC·Filed 1998·Granted Dec 12, 2000·203 cites·36 claims
- 1097US5721237AProtein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation propertiesRHONE POULENC RORER PHARMA·Filed 1995·Granted Feb 24, 1998·245 cites·13 claims
- 1197US5714493AAryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1994·Granted Feb 3, 1998·176 cites·1 claims
- 1297US5656643ABis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1995·Granted Aug 12, 1997·258 cites·4 claims
- 1396US6699873B1Melanocortin-4 receptor binding compounds and methods of use thereofMILLENNIUM PHARM INC·Filed 2001·Granted Mar 2, 2004·86 cites·35 claims
- 1495US5795889ABis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1995·Granted Aug 18, 1998·59 cites·17 claims
- 1593US6645969B1Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseAVENTIS PHARMA INC·Filed 1995·Granted Nov 11, 2003·74 cites·12 claims
- 1693USRE37650EAryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseAVENTIS PHARMACETICAL PRODUCTS·Filed 1994·Granted Apr 9, 2002·88 cites·5 claims
- 1792US10117848B2Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2016·Granted Nov 6, 2018·3 cites·39 claims
- 1892US2024366552A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1991US6846815B2Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2003·Granted Jan 25, 2005·28 cites·18 claims
- 2091US2025090488A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2190US10010523B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2017·Granted Jul 3, 2018·4 cites·1 claims
- 2290US2025332137A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2390US2024115543A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2489US2024277652A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2588US2023414553A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2688US2023255923A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2787US6559313B2Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic propertiesAVENTIS PHARMA GMBH·Filed 2002·Granted May 6, 2003·21 cites·2 claims
- 2886US10010522B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2017·Granted Jul 3, 2018·2 cites·1 claims
- 2986US2023157990A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3085US10010524B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2017·Granted Jul 3, 2018·2 cites·4 claims
- 3184US9737503B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2016·Granted Aug 22, 2017·2 cites·4 claims
- 3284US9463179B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2015·Granted Oct 11, 2016·2 cites·12 claims
- 3384US6696434B2Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2002·Granted Feb 24, 2004·14 cites·62 claims
- 3483US2022296556A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3582US9227918B2Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2014·Granted Jan 5, 2016·2 cites·7 claims
- 3682US6376472B1Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic propertiesAVENTIS PHARMA INC·Filed 1998·Granted Apr 23, 2002·24 cites·15 claims
- 3782US2022142963A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3882US2025195462A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3981US2021315855A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4081US2022040139A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4179US2021059972A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4279US2019269643A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4378US2021205258A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4476US2020368195A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4576US2019022048A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4675US2020230097A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4774US2020121631A1Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4874US2019380993A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4972US2019142781A1Short acting phenylalkylamine calcium channel blockers and uses thereofMILESTONE PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 5071US6921821B2Antagonists of melanin concentrating hormone receptorABBOTT LAB·Filed 2003·Granted Jul 26, 2005·7 cites·23 claims
Showing the top 50 of 62 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →